Loading...

Karen L Reckamp

Title(s)HS Clinical Professor, Medicine
SchoolMedicine
Address760 Westwood Plaza B8-146
Los Angeles CA 90024
Phone6262564673
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Combination of Immunotherapy and Antiangiogenic Therapy in Cancer-a Rational Approach. J Thorac Oncol. 2021 Feb; 16(2):178-182. PMID: 33494922.
      View in: PubMed   Mentions:
    2. Co-stimulatory and co-inhibitory immune markers in solid tumors with MET alterations. Future Sci OA. 2020 Nov 25; 7(2):FSO662. PMID: 33437521.
      View in: PubMed   Mentions:
    3. Role of immunotherapy and co-mutations on KRAS-mutant non-small cell lung cancer survival. J Thorac Dis. 2020 Sep; 12(9):5086-5095. PMID: 33145085.
      View in: PubMed   Mentions:
    4. Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2020 08 27; 383(9):813-824. Drilon A, Oxnard GR, Tan DSW, Loong HHF, Johnson M, Gainor J, McCoach CE, Gautschi O, Besse B, Cho BC, Peled N, Weiss J, Kim YJ, Ohe Y, Nishio M, Park K, Patel J, Seto T, Sakamoto T, Rosen E, Shah MH, Barlesi F, Cassier PA, Bazhenova L, De Braud F, Garralda E, Velcheti V, Satouchi M, Ohashi K, Pennell NA, Reckamp KL, Dy GK, Wolf J, Solomon B, Falchook G, Ebata K, Nguyen M, Nair B, Zhu EY, Yang L, Huang X, Olek E, Rothenberg SM, Goto K, Subbiah V. PMID: 32846060.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    5. A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN 14-179. Cancer. 2020 Oct 01; 126(19):4353-4361. PMID: 32697352.
      View in: PubMed   Mentions:
    6. Immunotherapy in Advanced Lung Cancer. Oncology (Williston Park). 2020 Jul 15; 34(7):272-279. PMID: 32674216.
      View in: PubMed   Mentions:
    7. Evaluation of Omics-Based Strategies for the Management of Advanced Lung Cancer. JCO Oncol Pract. 2021 Feb; 17(2):e257-e265. PMID: 32639928.
      View in: PubMed   Mentions:
    8. Duration of Targeted Therapy in Patients With Advanced Non-small-cell Lung Cancer Identified by Circulating Tumor DNA Analysis. Clin Lung Cancer. 2020 11; 21(6):545-552.e1. PMID: 32665165.
      View in: PubMed   Mentions:
    9. Immunotherapy in Advanced Non-Small Cell Lung Cancer. Semin Respir Crit Care Med. 2020 Jun; 41(3):400-408. PMID: 32450594.
      View in: PubMed   Mentions:
    10. Association of molecular characteristics with survival in advanced non-small cell lung cancer patients treated with checkpoint inhibitors. Lung Cancer. 2020 08; 146:174-181. PMID: 32554069.
      View in: PubMed   Mentions:
    11. Non-Small Cell Lung Cancer Patient Preferences for First-Line Treatment: A Discrete Choice Experiment. MDM Policy Pract. 2020 Jan-Jun; 5(1):2381468320922208. PMID: 32548305.
      View in: PubMed   Mentions:
    12. Engaging Patients in Precision Oncology: Development and Usability of a Web-Based Patient-Facing Genomic Sequencing Report. JCO Precis Oncol. 2020; 4. PMID: 32923887.
      View in: PubMed   Mentions:
    13. Molecular Targets Beyond the Big 3. Thorac Surg Clin. 2020 May; 30(2):157-164. PMID: 32327174.
      View in: PubMed   Mentions:
    14. Phase Ib Study of Crizotinib plus Pembrolizumab in Patients with Previously Untreated Advanced Non-Small Cell Lung Cancer with ALK Translocation. Oncologist. 2020 07; 25(7):562-e1012. Patel SP, Pakkala S, Pennell NA, Reckamp KL, Lanzalone S, Polli A, Tarazi J, Robert-Vizcarrondo F. PMID: 32048771.
      View in: PubMed   Mentions: 1     Fields:    
    15. Precision medicine and actionable alterations in lung cancer: A single institution experience. PLoS One. 2020; 15(2):e0228188. PMID: 32045431.
      View in: PubMed   Mentions:
    16. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020. J Natl Compr Canc Netw. 2019 12; 17(12):1464-1472. Ettinger DS, Wood DE, Aggarwal C, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, D'Amico TA, Dilling TJ, Dobelbower M, Gettinger S, Govindan R, Gubens MA, Hennon M, Horn L, Lackner RP, Lanuti M, Leal TA, Lin J, Loo BW, Martins RG, Otterson GA, Patel SP, Reckamp KL, Riely GJ, Schild SE, Shapiro TA, Stevenson J, Swanson SJ, Tauer KW, Yang SC, Gregory K, Hughes M. PMID: 31805526.
      View in: PubMed   Mentions: 51     Fields:    Translation:Humans
    17. Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial. J Thorac Oncol. 2020 03; 15(3):404-415. PMID: 31756496.
      View in: PubMed   Mentions:
    18. A phase 2 study of lenvatinib in patients with RET fusion-positive lung adenocarcinoma. Lung Cancer. 2019 12; 138:124-130. PMID: 31710864.
      View in: PubMed   Mentions:
    19. Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung Cancer. J Thorac Oncol. 2019 11; 14(11):1901-1911. Horn L, Whisenant JG, Wakelee H, Reckamp KL, Qiao H, Leal TA, Du L, Hernandez J, Huang V, Blumenschein GR, Waqar SN, Patel SP, Nieva J, Oxnard GR, Sanborn RE, Shaffer T, Garg K, Holzhausen A, Harrow K, Liang C, Lim LP, Li M, Lovly CM. PMID: 31446141.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    20. Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating RET Alterations and Oncogenic Signaling Pathway Aberrations. Clin Cancer Res. 2019 10 01; 25(19):5832-5842. Rich TA, Reckamp KL, Chae YK, Doebele RC, Iams WT, Oh M, Raymond VM, Lanman RB, Riess JW, Stinchcombe TE, Subbiah V, Trevarthen DR, Fairclough S, Yen J, Gautschi O. PMID: 31300450.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    21. Optimal adjuvant therapy in clinically N2 non-small cell lung cancer patients undergoing neoadjuvant chemotherapy and surgery: The importance of pathological response and lymph node ratio. Lung Cancer. 2019 07; 133:136-143. PMID: 31200820.
      View in: PubMed   Mentions:
    22. Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-small Cell Lung Cancer. Clin Cancer Res. 2019 Aug 01; 25(15):4691-4700. PMID: 30988079.
      View in: PubMed   Mentions:
    23. Anaplastic Lymphoma Kinase (ALK)-positive Tumors: Clinical, Radiographic and Molecular Profiles, and Uncommon Sites of Metastases in Patients With Lung Adenocarcinoma. Am J Clin Oncol. 2019 04; 42(4):337-344. PMID: 30741758.
      View in: PubMed   Mentions:
    24. Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303). Front Oncol. 2019; 9:132. Reckamp KL, Frankel PH, Ruel N, Mack PC, Gitlitz BJ, Li T, Koczywas M, Gadgeel SM, Cristea MC, Belani CP, Newman EM, Gandara DR, Lara PN. PMID: 30915273.
      View in: PubMed   Mentions:
    25. Variable Response to ALK Inhibitors in NSCLC with a Novel MYT1L-ALK Fusion. J Thorac Oncol. 2019 02; 14(2):e29-e30. PMID: 30683295.
      View in: PubMed   Mentions:
    26. EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes. J Clin Oncol. 2019 02 01; 37(4):278-285. Marcoux N, Gettinger SN, O'Kane G, Arbour KC, Neal JW, Husain H, Evans TL, Brahmer JR, Muzikansky A, Bonomi PD, Del Prete S, Wurtz A, Farago AF, Dias-Santagata D, Mino-Kenudson M, Reckamp KL, Yu HA, Wakelee HA, Shepherd FA, Piotrowska Z, Sequist LV. PMID: 30550363.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    27. A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105. Cancer Discov. 2019 03; 9(3):384-395. Drilon A, Fu S, Patel MR, Fakih M, Wang D, Olszanski AJ, Morgensztern D, Liu SV, Cho BC, Bazhenova L, Rodriguez CP, Doebele RC, Wozniak A, Reckamp KL, Seery T, Nikolinakos P, Hu Z, Oliver JW, Trone D, McArthur K, Patel R, Multani PS, Ahn MJ. PMID: 30487236.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    28. Inhibiting crosstalk between MET signaling and mitochondrial dynamics and morphology: a novel therapeutic approach for lung cancer and mesothelioma. . 2018; 19(11):1023-1032. PMID: 30311833.
      View in: PubMed   Mentions:
    29. Comparative efficacy of brigatinib versus ceritinib and alectinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small cell lung cancer. Curr Med Res Opin. 2019 04; 35(4):569-576. PMID: 30286627.
      View in: PubMed   Mentions:
    30. A phase I trial of topotecan plus tivantinib in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2018 10; 82(4):723-732. Liu SV, Groshen SG, Kelly K, Reckamp KL, Belani C, Synold TW, Goldkorn A, Gitlitz BJ, Cristea MC, Gong IY, Semrad TJ, Xu Y, Xu T, Koczywas M, Gandara DR, Newman EM. PMID: 30128950.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    31. The Anticancer Activity of a First-in-class Small-molecule Targeting PCNA. Clin Cancer Res. 2018 12 01; 24(23):6053-6065. PMID: 29967249.
      View in: PubMed   Mentions:
    32. Real-World Pseudoprogression: an Uncommon Phenomenon. J Thorac Oncol. 2018 07; 13(7):880-882. PMID: 29935844.
      View in: PubMed   Mentions:
    33. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018. J Natl Compr Canc Netw. 2018 07; 16(7):807-821. Ettinger DS, Aisner DL, Wood DE, Akerley W, Bauman J, Chang JY, Chirieac LR, D'Amico TA, Dilling TJ, Dobelbower M, Govindan R, Gubens MA, Hennon M, Horn L, Lackner RP, Lanuti M, Leal TA, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Patel SP, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M. PMID: 30006423.
      View in: PubMed   Mentions: 111     Fields:    Translation:Humans
    34. Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer. Lung Cancer. 2018 09; 123:91-98. Garon EB, Siegfried JM, Stabile LP, Young PA, Marquez-Garban DC, Park DJ, Patel R, Hu EH, Sadeghi S, Parikh RJ, Reckamp KL, Adams B, Elashoff RM, Elashoff D, Grogan T, Wang HJ, Dacic S, Brennan M, Valdes Y, Davenport S, Dubinett SM, Press MF, Slamon DJ, Pietras RJ. PMID: 30089602.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    35. Preparing Cancer Patients and Family Caregivers for Lung Surgery: Development of a Multimedia Self-Management Intervention. J Cancer Educ. 2018 06; 33(3):557-563. PMID: 27542378.
      View in: PubMed   Mentions:
    36. Therapeutic antibodies: A new era in the treatment of respiratory diseases? Pharmacol Ther. 2018 09; 189:149-172. PMID: 29730443.
      View in: PubMed   Mentions:
    37. Targeted Therapy for Patients With Metastatic Non-Small Cell Lung Cancer. J Natl Compr Canc Netw. 2018 05; 16(5S):601-604. PMID: 29784736.
      View in: PubMed   Mentions:
    38. Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study. Clin Cancer Res. 2018 06 15; 24(12):2771-2779. PMID: 29563138.
      View in: PubMed   Mentions:
    39. Hybrid Capture-Based Comprehensive Genomic Profiling Identifies Lung Cancer Patients with Well-Characterized Sensitizing Epidermal Growth Factor Receptor Point Mutations That Were Not Detected by Standard of Care Testing. Oncologist. 2018 07; 23(7):776-781. PMID: 29540602.
      View in: PubMed   Mentions:
    40. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). J Clin Oncol. 2017 Dec 10; 35(35):3924-3933. PMID: 29023213.
      View in: PubMed   Mentions:
    41. Urine test for EGFR analysis in patients with non-small cell lung cancer. J Thorac Dis. 2017 Oct; 9(Suppl 13):S1323-S1331. PMID: 29184671.
      View in: PubMed   Mentions:
    42. Triptolide-Assisted Phosphorylation of p53 Suppresses Inflammation-Induced NF-?B Survival Pathways in Cancer Cells. Mol Cell Biol. 2017 08 01; 37(15). PMID: 28533220.
      View in: PubMed   Mentions:
    43. Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance). J Clin Oncol. 2017 Jul 01; 35(19):2184-2192. Edelman MJ, Wang X, Hodgson L, Cheney RT, Baggstrom MQ, Thomas SP, Gajra A, Bertino E, Reckamp KL, Molina J, Schiller JH, Mitchell-Richards K, Friedman PN, Ritter J, Milne G, Hahn OM, Stinchcombe TE, Vokes EE, . PMID: 28489511.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    44. Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial. J Clin Oncol. 2017 Aug 01; 35(22):2490-2498. PMID: 28475456.
      View in: PubMed   Mentions:
    45. Phase I Trial of Intratumoral Injection of CCL21 Gene-Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8+ T-cell Infiltration. Clin Cancer Res. 2017 Aug 15; 23(16):4556-4568. Lee JM, Lee MH, Garon E, Goldman JW, Salehi-Rad R, Baratelli FE, Schaue D, Wang G, Rosen F, Yanagawa J, Walser TC, Lin Y, Park SJ, Adams S, Marincola FM, Tumeh PC, Abtin F, Suh R, Reckamp KL, Lee G, Wallace WD, Lee S, Zeng G, Elashoff DA, Sharma S, Dubinett SM. PMID: 28468947.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCellsCTClinical Trials
    46. Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 04; 15(4):504-535. Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman J, Chirieac LR, D'Amico TA, DeCamp MM, Dilling TJ, Dobelbower M, Doebele RC, Govindan R, Gubens MA, Hennon M, Horn L, Komaki R, Lackner RP, Lanuti M, Leal TA, Leisch LJ, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M. PMID: 28404761.
      View in: PubMed   Mentions: 268     Fields:    Translation:Humans
    47. A Multimedia Self-management Intervention to Prepare Cancer Patients and Family Caregivers for Lung Surgery and Postoperative Recovery. Clin Lung Cancer. 2017 05; 18(3):e151-e159. PMID: 28233696.
      View in: PubMed   Mentions:
    48. Immunotherapy improves the prognosis of lung cancer: do we have to change intensive care unit admission and triage guidelines? Crit Care. 2017 Jan 27; 21(1):18. PMID: 28126007.
      View in: PubMed   Mentions:
    49. A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. 2017 03; 12(3):556-566. Gandara DR, Leighl N, Delord JP, Barlesi F, Bennouna J, Zalcman G, Infante JR, Reckamp KL, Kelly K, Shepherd FA, Mazieres J, Janku F, Gardner OS, Mookerjee B, Wu Y, Cox DS, Schramek D, Peddareddigari V, Liu Y, D'Amelio AM, Blumenschein G. PMID: 27876675.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    50. The impact of lung cancer surgery on quality of life trajectories in patients and family caregivers. Lung Cancer. 2016 11; 101:35-39. PMID: 27794406.
      View in: PubMed   Mentions:
    51. A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma. J Thorac Oncol. 2016 Oct; 11(10):1690-700. PMID: 27468937.
      View in: PubMed   Mentions:
    52. NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016. J Natl Compr Canc Netw. 2016 07; 14(7):825-36. Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Dilling T, Dobelbower M, Govindan R, Hennon M, Horn L, Jahan TM, Komaki R, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Sharma N, Swanson SJ, Stevenson J, Tauer K, Yang SC, Gregory K, Hughes M. PMID: 27407123.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    53. Therapeutic monoclonal antibodies for respiratory diseases: Current challenges and perspectives, March 31 - April 1, 2016, Tours, France. MAbs. 2016 Aug-Sep; 8(6):999-1009. PMID: 27266390.
      View in: PubMed   Mentions:
    54. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016. J Natl Compr Canc Netw. 2016 03; 14(3):255-64. Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Dilling TJ, Dobelbower MC, Govindan R, Hennon M, Horn L, Jahan TM, Komaki R, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Sharma N, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M. PMID: 26957612.
      View in: PubMed   Mentions: 137     Fields:    Translation:Humans
    55. Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer. Ann Oncol. 2016 Apr; 27(4):693-9. Carter CA, Rajan A, Keen C, Szabo E, Khozin S, Thomas A, Brzezniak C, Guha U, Doyle LA, Steinberg SM, Xi L, Raffeld M, Tomita Y, Lee MJ, Lee S, Trepel JB, Reckamp KL, Koehler S, Gitlitz B, Salgia R, Gandara D, Vokes E, Giaccone G. PMID: 26802155.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    56. Advances in immunotherapy for non-small cell lung cancer. Clin Adv Hematol Oncol. 2015 Dec; 13(12):847-53. PMID: 27058851.
      View in: PubMed   Mentions:
    57. Long-Term Effect of an Interdisciplinary Supportive Care Intervention for Lung Cancer Survivors After Surgical Procedures. Ann Thorac Surg. 2016 Feb; 101(2):495-502; discussion 502-3. PMID: 26443881.
      View in: PubMed   Mentions:
    58. Interdisciplinary Palliative Care for Patients With Lung Cancer. J Pain Symptom Manage. 2015 Dec; 50(6):758-67. PMID: 26296261.
      View in: PubMed   Mentions:
    59. Serum LAMC2 enhances the prognostic value of a multi-parametric panel in non-small cell lung cancer. Br J Cancer. 2015 Jul 28; 113(3):484-91. PMID: 26180921.
      View in: PubMed   Mentions:
    60. Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib. Clin Cancer Res. 2015 Oct 01; 21(19):4321-6. Lara PN, Longmate J, Mack PC, Kelly K, Socinski MA, Salgia R, Gitlitz B, Li T, Koczywas M, Reckamp KL, Gandara DR. PMID: 26106072.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    61. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015 Jul 09; 373(2):123-35. PMID: 26028407.
      View in: PubMed   Mentions:
    62. Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced non-small cell lung cancer. Cancer. 2015 Sep 15; 121(18):3298-306. Reckamp KL, Koczywas M, Cristea MC, Dowell JE, Wang HJ, Gardner BK, Milne GL, Figlin RA, Fishbein MC, Elashoff RM, Dubinett SM. PMID: 26033830.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    63. Non-Small Cell Lung Cancer, Version 6.2015. J Natl Compr Canc Netw. 2015 May; 13(5):515-24. Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Dilling TJ, Dobelbower MC, Govindan R, Grannis FW, Horn L, Jahan TM, Komaki R, Krug LM, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Schild SE, Shapiro TA, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M, . PMID: 25964637.
      View in: PubMed   Mentions: 141     Fields:    Translation:Humans
    64. Non-small cell lung cancer, version 1.2015. J Natl Compr Canc Netw. 2014 Dec; 12(12):1738-61. Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Dilling TJ, Govindan R, Grannis FW, Horn L, Jahan TM, Komaki R, Kris MG, Krug LM, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Schild S, Shapiro TA, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M. PMID: 25505215.
      View in: PubMed   Mentions: 62     Fields:    Translation:Humans
    65. Phase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumors. Br J Cancer. 2014 Dec 09; 111(12):2268-74. Koczywas M, Frankel PH, Synold TW, Lenz HJ, Mortimer JE, El-Khoueiry AB, Gandara DR, Cristea MC, Chung VM, Lim D, Reckamp KL, Lau DH, Doyle LA, Ruel C, Carroll MI, Newman EM. PMID: 25349975.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    66. Future of ALK inhibition in non-small-cell lung cancer. Lancet Oncol. 2014 Sep; 15(10):1047-9. PMID: 25153539.
      View in: PubMed   Mentions:
    67. Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab. Target Oncol. 2015 Mar; 10(1):65-76. PMID: 24816908.
      View in: PubMed   Mentions:
    68. The FEN1 E359K germline mutation disrupts the FEN1-WRN interaction and FEN1 GEN activity, causing aneuploidy-associated cancers. Oncogene. 2015 Feb 12; 34(7):902-11. PMID: 24608430.
      View in: PubMed   Mentions:
    69. A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib. Cancer. 2014 Apr 15; 120(8):1145-54. PMID: 24501009.
      View in: PubMed   Mentions:
    70. PGE2-driven expression of c-Myc and oncomiR-17-92 contributes to apoptosis resistance in NSCLC. Mol Cancer Res. 2014 May; 12(5):765-74. Krysan K, Kusko R, Grogan T, O'Hearn J, Reckamp KL, Walser TC, Garon EB, Lenburg ME, Sharma S, Spira AE, Elashoff D, Dubinett SM. PMID: 24469837.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    71. EGFR-mutated lung cancer with T790M-acquired resistance in the brain and histologic transformation in the lung. J Natl Compr Canc Netw. 2013 Sep 01; 11(9):1040-4. Scher KS, Saldivar JS, Fishbein M, Marchevsky A, Reckamp KL. PMID: 24029120.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    72. Sexuality, lung cancer, and the older adult: an unlikely trio? J Adv Pract Oncol. 2013 Sep; 4(5):331-40. PMID: 25032012.
      View in: PubMed   Mentions:
    73. Elevated neutrophil gelatinase-associated lipocalin contributes to erlotinib resistance in non-small cell lung cancer. Am J Transl Res. 2013; 5(5):481-96. Krysan K, Cui X, Gardner BK, Reckamp KL, Wang X, Hong L, Walser TC, Rodriguez NL, Pagano PC, Garon EB, Brothers JF, Elashoff D, Lee JM, Spira AE, Sharma S, Fishbein MC, Dubinett SM. PMID: 23977408.
      View in: PubMed   Mentions:
    74. Non-small cell lung cancer, version 2.2013. J Natl Compr Canc Netw. 2013 Jun 01; 11(6):645-53; quiz 653. Ettinger DS, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Govindan R, Grannis FW, Grant SC, Horn L, Jahan TM, Komaki R, Kong FM, Kris MG, Krug LM, Lackner RP, Lennes IT, Loo BW, Martins R, Otterson GA, Patel JD, Pinder-Schenck MC, Pisters KM, Reckamp K, Riely GJ, Rohren E, Shapiro TA, Swanson SJ, Tauer K, Wood DE, Yang SC, Gregory K, Hughes M, . PMID: 23744864.
      View in: PubMed   Mentions: 151     Fields:    Translation:Humans
    75. Myeloid clusters are associated with a pro-metastatic environment and poor prognosis in smoking-related early stage non-small cell lung cancer. PLoS One. 2013; 8(5):e65121. Zhang W, Pal SK, Liu X, Yang C, Allahabadi S, Bhanji S, Figlin RA, Yu H, Reckamp KL. PMID: 23717691.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    76. Thymomas and thymic carcinomas: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2013 May 01; 11(5):562-76. Ettinger DS, Riely GJ, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Govindan R, Grannis FW, Grant SC, Horn L, Jahan TM, Komaki R, Kong FM, Kris MG, Krug LM, Lackner RP, Lennes IT, Loo BW, Martins R, Otterson GA, Patel JD, Pinder-Schenck MC, Pisters KM, Reckamp K, Rohren E, Shapiro TA, Swanson SJ, Tauer K, Wood DE, Yang SC, Gregory K, Hughes M, . PMID: 23667206.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    77. Intraventricular chemotherapy for leptomeningeal carcinomatosis from lung cancer: a feasible and beneficial treatment option? J Thorac Oncol. 2013 May; 8(5):523-4. PMID: 23584292.
      View in: PubMed   Mentions:
    78. A 75-year-old man with progressive bronchioalveolar carcinoma. Semin Oncol. 2013 Feb; 40(1):e1-8. PMID: 23391120.
      View in: PubMed   Mentions:
    79. CCL21 Chemokine Therapy for Lung Cancer. Int Trends Immun. 2013 Jan; 1(1):10-15. Sharma S, Zhu L, Srivastava MK, Harris-White M, Huang M, Lee JM, Rosen F, Lee G, Wang G, Kickhoefer V, Rome LH, Baratelli F, St John M, Reckamp K, Chul-Yang S, Hillinger S, Strieter R, Dubinett S. PMID: 25264541.
      View in: PubMed   Mentions:
    80. Phosphatidylinositol-3-kinase pathway. J Thorac Oncol. 2012 Dec; 7(16 Suppl 5):S383-4. PMID: 23160326.
      View in: PubMed   Mentions:
    81. Longitudinal changes in function, symptom burden, and quality of life in patients with early-stage lung cancer. Ann Surg Oncol. 2013 Jun; 20(6):1788-97. PMID: 23143593.
      View in: PubMed   Mentions:
    82. Non-small cell lung cancer. J Natl Compr Canc Netw. 2012 Oct 01; 10(10):1236-71. Ettinger DS, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW, Horn L, Jahan TM, Jahanzeb M, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Lennes IT, Loo BW, Martins R, O'Malley J, Osarogiagbon RU, Otterson GA, Patel JD, Pinder-Schenck MC, Pisters KM, Reckamp K, Riely GJ, Rohren E, Swanson SJ, Wood DE, Yang SC, Hughes M, Gregory KM, . PMID: 23054877.
      View in: PubMed   Mentions: 128     Fields:    Translation:Humans
    83. Is benefit of maintenance therapy for NSCLC best defined by progression-free survival? Lancet Oncol. 2012 May; 13(5):435-6. PMID: 22512846.
      View in: PubMed   Mentions:
    84. Antiangiogenic agents as second-line therapy for advanced non-small cell lung cancer. Cancer Lett. 2012 Aug 28; 321(2):101-9. PMID: 22306704.
      View in: PubMed   Mentions:
    85. Malignant pleural mesothelioma. J Natl Compr Canc Netw. 2012 Jan; 10(1):26-41. Ettinger DS, Akerley W, Borghaei H, Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW, Horn L, Jahan TM, Jahanzeb M, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Lennes IT, Loo BW, Martins R, O'Malley J, Osarogiagbon RU, Otterson GA, Patel JD, Schenck MP, Pisters KM, Reckamp K, Riely GJ, Rohren E, Swanson SJ, Wood DE, Yang SC, . PMID: 22223867.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    86. (18)F-FDG PET/CT for monitoring treatment responses to the epidermal growth factor receptor inhibitor erlotinib. J Nucl Med. 2011 Nov; 52(11):1684-1689. Benz MR, Herrmann K, Walter F, Garon EB, Reckamp KL, Figlin R, Phelps ME, Weber WA, Czernin J, Allen-Auerbach MS. PMID: 22045706.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCTClinical Trials
    87. Novel mechanisms and targets: miscellaneous agents. J Thorac Oncol. 2011 Nov; 6(11 Suppl 4):S1812-4. PMID: 22005541.
      View in: PubMed   Mentions:
    88. Bortezomib for patients with advanced-stage bronchioloalveolar carcinoma: a California Cancer Consortium Phase II study (NCI 7003). J Thorac Oncol. 2011 Oct; 6(10):1741-5. Ramalingam SS, Davies AM, Longmate J, Edelman MJ, Lara PN, Vokes EE, Villalona-Calero M, Gitlitz B, Reckamp K, Salgia R, Wright JJ, Belani CP, Gandara DR. PMID: 21716143.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    89. Antiangiogenic and antimetastatic activity of JAK inhibitor AZD1480. Cancer Res. 2011 Nov 01; 71(21):6601-10. Xin H, Herrmann A, Reckamp K, Zhang W, Pal S, Hedvat M, Zhang C, Liang W, Scuto A, Weng S, Morosini D, Cao ZA, Zinda M, Figlin R, Huszar D, Jove R, Yu H. PMID: 21920898.
      View in: PubMed   Mentions: 56     Fields:    Translation:HumansAnimalsCells
    90. A phase I study of bortezomib and temozolomide in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2012 Feb; 69(2):505-14. PMID: 21850464.
      View in: PubMed   Mentions:
    91. Combination chemotherapy for older adults with advanced non-small-cell lung cancer. Lancet. 2011 Sep 17; 378(9796):1055-7. PMID: 21831419.
      View in: PubMed   Mentions:
    92. A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer. Ann Oncol. 2011 Sep; 22(9):2057-2067. PMID: 21321086.
      View in: PubMed   Mentions:
    93. Management of non-small-cell lung cancer in the older adult. Maturitas. 2011 Apr; 68(4):311-21. PMID: 21295421.
      View in: PubMed   Mentions:
    94. City of Hope Cancer Center hematology-oncology fellowship and hematopoietic stem cell transplantation fellowship. Am J Hematol. 2011 Feb; 86(2):197-8. PMID: 21264906.
      View in: PubMed   Mentions:
    95. Predictors of finding benefit after lung cancer diagnosis. Psychooncology. 2012 Apr; 21(4):365-73. Thornton AA, Owen JE, Kernstine K, Koczywas M, Grannis F, Cristea M, Reckamp K, Stanton AL. PMID: 21254308.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    96. STAT3: a target to enhance antitumor immune response. Curr Top Microbiol Immunol. 2011; 344:41-59. Lee H, Pal SK, Reckamp K, Figlin RA, Yu H. PMID: 20517723.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansAnimalsCells
    97. Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial. Clin Lung Cancer. 2011 Jan; 12(1):33-7. Lara PN, Longmate J, Reckamp K, Gitlitz B, Argiris A, Ramalingam S, Belani CP, Mack PC, Lau DH, Koczywas M, Wright JJ, Shepherd FA, Leighl N, Gandara DR. PMID: 21273177.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    98. Mammalian target of rapamycin, Akt, and phosphatidylinositol 3-kinase signaling. J Thorac Oncol. 2010 Dec; 5(12 Suppl 6):S487-9. PMID: 21102251.
      View in: PubMed   Mentions:
    99. Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects. Cancer Res. 2010 Dec 01; 70(23):9599-610. Kujawski M, Zhang C, Herrmann A, Reckamp K, Scuto A, Jensen M, Deng J, Forman S, Figlin R, Yu H. PMID: 21118964.
      View in: PubMed   Mentions: 51     Fields:    Translation:AnimalsCells
    100. Thymic malignancies. J Natl Compr Canc Netw. 2010 Nov; 8(11):1302-15. Ettinger DS, Akerley W, Bepler G, Blum MG, Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Govindan R, Grannis FW, Jahan T, Johnson DH, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Le QT, Lennes IT, Martins R, O'Malley J, Osarogiagbon RU, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Swanson SJ, Wood DE, Yang SC. PMID: 21081786.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    101. Biomarker-based phase I dose-escalation, pharmacokinetic, and pharmacodynamic study of oral apricoxib in combination with erlotinib in advanced nonsmall cell lung cancer. Cancer. 2011 Feb 15; 117(4):809-18. Reckamp K, Gitlitz B, Chen LC, Patel R, Milne G, Syto M, Jezior D, Zaknoen S. PMID: 20922800.
      View in: PubMed   Mentions:
    102. Akt inhibitors in clinical development for the treatment of cancer. Expert Opin Investig Drugs. 2010 Nov; 19(11):1355-66. Pal SK, Reckamp K, Yu H, Figlin RA. PMID: 20846000.
      View in: PubMed   Mentions: 100     Fields:    Translation:HumansAnimals
    103. Targeting Stat3 in the myeloid compartment drastically improves the in vivo antitumor functions of adoptively transferred T cells. Cancer Res. 2010 Oct 01; 70(19):7455-64. Herrmann A, Kortylewski M, Kujawski M, Zhang C, Reckamp K, Armstrong B, Wang L, Kowolik C, Deng J, Figlin R, Yu H. PMID: 20841481.
      View in: PubMed   Mentions: 47     Fields:    Translation:AnimalsCells
    104. Consistency of a two clinical site sample collection: a proteomics study. Proteomics Clin Appl. 2010 Sep; 4(8-9):726-38. Wiesner C, Hannum C, Reckamp K, Figlin R, Dubridge R, Roy SM, Lin S, Becker CH, Jones T, Hiller J, Cheville JC, Wilson K. PMID: 21137090.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    105. Non-small cell lung cancer. J Natl Compr Canc Netw. 2010 Jul; 8(7):740-801. Ettinger DS, Akerley W, Bepler G, Blum MG, Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW, Jahan T, Jahanzeb M, Johnson DH, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Le QT, Lennes IT, Martins R, O'Malley J, Osarogiagbon RU, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Simon GR, Swanson SJ, Wood DE, Yang SC. PMID: 20679538.
      View in: PubMed   Mentions: 207     Fields:    Translation:Humans
    106. PGE(2) contributes to TGF-beta induced T regulatory cell function in human non-small cell lung cancer. Am J Transl Res. 2010 Jun 30; 2(4):356-67. Baratelli F, Lee JM, Hazra S, Lin Y, Walser TC, Schaue D, Pak PS, Elashoff D, Reckamp K, Zhang L, Fishbein MC, Sharma S, Dubinett SM. PMID: 20733946.
      View in: PubMed   Mentions:
    107. Targeted therapies for non-small cell lung cancer: an evolving landscape. . 2010 Jul; 9(7):1931-44. Pal SK, Figlin RA, Reckamp K. PMID: 20571071.
      View in: PubMed   Mentions:
    108. Molecular origins of lung cancer: prospects for personalized prevention and therapy. J Thorac Oncol. 2010 Jun; 5(6 Suppl 3):S207-13. PMID: 20502275.
      View in: PubMed   Mentions:
    109. Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancer. Clin Cancer Res. 2010 Jan 01; 16(1):279-90. PMID: 20028752.
      View in: PubMed   Mentions:
    110. Identification of five candidate lung cancer biomarkers by proteomics analysis of conditioned media of four lung cancer cell lines. Mol Cell Proteomics. 2009 Dec; 8(12):2746-58. Planque C, Kulasingam V, Smith CR, Reckamp K, Goodglick L, Diamandis EP. PMID: 19776420.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansAnimalsCells
    111. Summary of selected presentations from the 8th annual targeted therapy in lung cancer symposium. J Thorac Oncol. 2009 Jul; 4(7):930-5. Camidge R, Gaspar L, Goss G, Kelly K, Ramalingam S, Reckamp K, Simon G, Tsao M, West HJ, Herbst R, Johnson D, Bunn P, Govindan R. PMID: 19550249.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    112. CXCR4 expression on circulating pan-cytokeratin positive cells is associated with survival in patients with advanced non-small cell lung cancer. BMC Cancer. 2009 Jun 29; 9:213. Reckamp KL, Figlin RA, Burdick MD, Dubinett SM, Elashoff RM, Strieter RM. PMID: 19563666.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCells
    113. Non-small cell lung cancer in the elderly: defining treatment options. Semin Oncol. 2008 Dec; 35(6):590-6. PMID: 19027463.
      View in: PubMed   Mentions:
    114. An interdisciplinary care approach for integration of palliative care in lung cancer. Clin Lung Cancer. 2008 Nov; 9(6):352-60. PMID: 19073518.
      View in: PubMed   Mentions:
    115. The role of targeting mammalian target of rapamycin in lung cancer. Clin Lung Cancer. 2008 Nov; 9(6):340-5. Pal SK, Figlin RA, Reckamp KL. PMID: 19073516.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    116. NCCN Task Force Report: mTOR inhibition in solid tumors. J Natl Compr Canc Netw. 2008 Sep; 6 Suppl 5:S1-20; quiz S21-2. Figlin RA, Brown E, Armstrong AJ, Akerley W, Benson AB, Burstein HJ, Ettinger DS, Febbo PG, Fury MG, Hudes GR, Kies MS, Kwak EL, Morgan RJ, Mortimer J, Reckamp K, Venook AP, Worden F, Yen Y. PMID: 18926092.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    117. Chemokines as therapeutic targets in renal cell carcinoma. Expert Rev Anticancer Ther. 2008 Jun; 8(6):887-93. Reckamp KL, Strieter RM, Figlin RA. PMID: 18533798.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    118. A multiparametric serum kallikrein panel for diagnosis of non-small cell lung carcinoma. Clin Cancer Res. 2008 Mar 01; 14(5):1355-62. Planque C, Li L, Zheng Y, Soosaipillai A, Reckamp K, Chia D, Diamandis EP, Goodglick L. PMID: 18316555.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    119. Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase-9 and a decline in serum-soluble E-cadherin. J Thorac Oncol. 2008 Feb; 3(2):117-24. Reckamp KL, Gardner BK, Figlin RA, Elashoff D, Krysan K, Dohadwala M, Mao J, Sharma S, Inge L, Rajasekaran A, Dubinett SM. PMID: 18303430.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    120. Inflammation, epithelial to mesenchymal transition, and epidermal growth factor receptor tyrosine kinase inhibitor resistance. J Thorac Oncol. 2008 Feb; 3(2):107-10. Krysan K, Lee JM, Dohadwala M, Gardner BK, Reckamp KL, Garon E, St John M, Sharma S, Dubinett SM. PMID: 18303428.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells
    121. Inflammation and lung carcinogenesis: applying findings in prevention and treatment. Expert Rev Anticancer Ther. 2007 Oct; 7(10):1405-21. Peebles KA, Lee JM, Mao JT, Hazra S, Reckamp KL, Krysan K, Dohadwala M, Heinrich EL, Walser TC, Cui X, Baratelli FE, Garon E, Sharma S, Dubinett SM. PMID: 17944566.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansAnimals
    122. Expression of CXCR3 on mononuclear cells and CXCR3 ligands in patients with metastatic renal cell carcinoma in response to systemic IL-2 therapy. J Immunother. 2007 May-Jun; 30(4):417-24. Reckamp KL, Figlin RA, Moldawer N, Pantuck AJ, Belldegrun AS, Burdick MD, Strieter RM. PMID: 17457216.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    123. Stromal derived factor-1 (SDF-1/CXCL12) and CXCR4 in renal cell carcinoma metastasis. Mol Cancer. 2006 Nov 03; 5:56. Pan J, Mestas J, Burdick MD, Phillips RJ, Thomas GV, Reckamp K, Belperio JA, Strieter RM. PMID: 17083723.
      View in: PubMed   Mentions: 62     Fields:    Translation:HumansAnimalsCells
    124. A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer. Clin Cancer Res. 2006 Jun 01; 12(11 Pt 1):3381-8. Reckamp KL, Krysan K, Morrow JD, Milne GL, Newman RA, Tucker C, Elashoff RM, Dubinett SM, Figlin RA. PMID: 16740761.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCTClinical Trials
    125. The potential and rationale for COX-2 inhibitors in lung cancer. Anticancer Agents Med Chem. 2006 May; 6(3):209-20. Krysan K, Reckamp KL, Sharma S, Dubinett SM. PMID: 16712449.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansAnimals
    126. Intrapulmonary administration of CCL21 gene-modified dendritic cells reduces tumor burden in spontaneous murine bronchoalveolar cell carcinoma. Cancer Res. 2006 Mar 15; 66(6):3205-13. Yang SC, Batra RK, Hillinger S, Reckamp KL, Strieter RM, Dubinett SM, Sharma S. PMID: 16540672.
      View in: PubMed   Mentions: 27     Fields:    Translation:AnimalsCells
    127. The role of CXCR2/CXCR2 ligand biological axis in renal cell carcinoma. J Immunol. 2005 Oct 15; 175(8):5351-7. Mestas J, Burdick MD, Reckamp K, Pantuck A, Figlin RA, Strieter RM. PMID: 16210641.
      View in: PubMed   Mentions: 56     Fields:    Translation:HumansAnimalsCells
    128. Radiofrequency ablation in lung cancer: promising results in safety and efficacy. Oncology (Williston Park). 2005 Oct; 19(11 Suppl 4):12-21. Suh R, Reckamp K, Zeidler M, Cameron R. PMID: 16366374.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansPHPublic Health
    129. Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells. J Immunol. 2005 Aug 01; 175(3):1483-90. Baratelli F, Lin Y, Zhu L, Yang SC, Heuzé-Vourc'h N, Zeng G, Reckamp K, Dohadwala M, Sharma S, Dubinett SM. PMID: 16034085.
      View in: PubMed   Mentions: 169     Fields:    Translation:HumansCells
    130. Cyclooxygenase 2 inhibition promotes IFN-gamma-dependent enhancement of antitumor responses. J Immunol. 2005 Jul 15; 175(2):813-9. Sharma S, Zhu L, Yang SC, Zhang L, Lin J, Hillinger S, Gardner B, Reckamp K, Strieter RM, Huang M, Batra RK, Dubinett SM. PMID: 16002678.
      View in: PubMed   Mentions: 16     Fields:    Translation:AnimalsCells
    131. Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner. Cancer Res. 2005 Jul 15; 65(14):6275-81. Krysan K, Reckamp KL, Dalwadi H, Sharma S, Rozengurt E, Dohadwala M, Dubinett SM. PMID: 16024629.
      View in: PubMed   Mentions: 76     Fields:    Translation:HumansCells
    132. Chemoprevention strategies with cyclooxygenase-2 inhibitors for lung cancer. Clin Lung Cancer. 2005 Jul; 7(1):30-9. Mao JT, Cui X, Reckamp K, Liu M, Krysan K, Dalwadi H, Sharma S, Hazra S, Strieter R, Gardner B, Dubinett SM. PMID: 16098242.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    133. Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer. Cancer Res. 2005 Jun 15; 65(12):5211-20. Sharma S, Yang SC, Zhu L, Reckamp K, Gardner B, Baratelli F, Huang M, Batra RK, Dubinett SM. PMID: 15958566.
      View in: PubMed   Mentions: 139     Fields:    Translation:AnimalsCells
    134. PGE2 confers survivin-dependent apoptosis resistance in human monocyte-derived dendritic cells. J Leukoc Biol. 2005 Aug; 78(2):555-64. Baratelli F, Krysan K, Heuzé-Vourc'h N, Zhu L, Escuadro B, Sharma S, Reckamp K, Dohadwala M, Dubinett SM. PMID: 15908458.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells